PCOS hair loss: understanding the connection and choosing suitable care

Does thinning hair suggest that you have PCOS?

A widening parting deserves assessment, particularly alongside infrequent periods, new facial hair or persistent acne. These features help guide a clinical conversation rather than providing a home diagnosis. The 2023 international guideline explains that female pattern hair loss, when it occurs without hirsutism, is a relatively weak predictor of raised blood androgen levels (Teede et al., 2023).

In adults, PCOS is diagnosed from a combination of findings after other explanations have been considered. At least two features are required: ovulatory dysfunction, clinical or biochemical androgen excess, and a particular ovarian morphology. The latter may be assessed by ultrasound or, in appropriate adult circumstances, an AMH blood test. Neither an AMH result nor an ultrasound finding establishes the diagnosis on its own.

An ultrasound is unnecessary when irregular cycles and androgen excess already provide the required diagnostic features. Adolescents need a different assessment, and ovarian ultrasound or AMH should not be used to diagnose PCOS in this age group. The current NHS information uses the name polyendocrine metabolic ovarian syndrome, or PMOS, for the condition previously called PCOS. Both terms may therefore appear when you look for information or discuss your care.

Why can scalp thinning occur alongside increased body hair?

Androgens occur naturally in women and have functions in several tissues. Their production or activity may be increased in PCOS, but follicles in different body areas do not respond identically. Increased facial hair can therefore occur at the same time as miniaturisation of susceptible follicles on the scalp, rather than representing contradictory symptoms.

Miniaturisation means that affected follicles produce progressively finer shafts over successive growth cycles. This can reduce coverage around the parting and over the top of the head. It overlaps with the features of androgenetic alopecia, although female pattern hair loss cannot simply be explained by applying the mechanisms of male baldness to women (Fabbrocini et al., 2018).

Local follicle sensitivity also matters, and normal blood androgen levels do not exclude female pattern thinning. Understanding DHT and its effects on hair explains part of this process, without accounting for every case. Your hair’s appearance cannot reveal your testosterone concentration or reliably predict how your individual PCOS symptoms will change over time.

What should be assessed before the hair loss is attributed to PCOS?

Assessment starts with the timing of the changes: gradual thinning, a recent increase in shedding, or a change following illness, childbirth or medication. Mention scalp symptoms, styling habits and any treatments you have already tried, including supplements. Having PCOS does not rule out telogen effluvium, alopecia areata or another hair condition occurring at the same time.

A scalp examination considers the distribution of thinning and the condition of the skin. Trichoscopy uses magnification to assess hair diameter variation and other features that help distinguish different causes. Pain, inflammation or a suddenly bare patch needs reassessment, rather than automatically being treated as another consequence of PCOS. A blood result cannot replace this examination.

Tests are selected according to the associated symptoms and the clinical question. A doctor may investigate androgen excess when PCOS is suspected, or another contributor to shedding when the history suggests it. Hormonal contraception can alter some results, so provide its exact name without stopping it to prepare your own testing. Our discussion of hormonal factors in hair loss explains why blood measurements and scalp diagnosis answer different questions.

Rapidly increasing body hair, a change in your voice or other unusual developments warrant prompt medical advice. They should not automatically be attributed to an existing PCOS diagnosis. The purpose is to investigate the particular concern appropriately, rather than ordering the same extensive hormone panel for everyone who notices hair loss.

Where does topical minoxidil fit into treatment?

Once female pattern hair loss has been identified, topical minoxidil is one option to discuss. It acts on hair growth rather than treating the ovarian or metabolic features of PCOS. Evidence in female pattern hair loss supports its use, but does not establish an identical response for every person who also has PCOS (Fabbrocini et al., 2018).

The choice of preparation depends on its indication, your circumstances and how well you tolerate it. Scalp irritation and unwanted facial hair can occur, and some people experience a temporary increase in shedding after starting treatment. That early shedding does not, by itself, prove that treatment will succeed. If it concerns you or other symptoms develop, contact the clinician or pharmacist supporting your treatment.

Oral minoxidil has different risks and monitoring requirements from a scalp preparation. Switching from a scalp product to tablets requires assessment by a prescriber. Tell the clinician about pregnancy plans, pregnancy or breastfeeding before treatment: the NHS hospital leaflet advises against minoxidil in these circumstances because safety has not been established. An online dosing routine cannot establish whether a particular preparation is suitable for you.

Contraception and antiandrogens involve more than a hair decision

A combined contraceptive pill may be offered for irregular menstrual cycles or hirsutism. The choice takes account of contraceptive needs, contraindications and potential harms, including vascular risks. Improvement in periods or acne does not necessarily demonstrate a benefit for scalp hair. There is no single pill that suits everyone with PCOS, and changing an existing prescription requires an individual discussion.

For female pattern hair loss, the 2023 guideline allows consideration of an antiandrogen with a combined pill, while explicitly acknowledging the shortage of evidence specific to PCOS. The review by Alesi and colleagues primarily assesses hirsutism and hormonal or metabolic outcomes. Its findings cannot provide a reliable scalp regrowth rate, and the certainty of much of the evidence is low.

Spironolactone may be considered by a prescriber in selected cases; UK prescribing for this hair condition falls outside its licensed indications. Possible problems include dizziness, menstrual changes and increased potassium, with kidney health and other medicines influencing suitability. Blood pressure and blood tests are monitored as appropriate, and the NHS hospital leaflet describes checking potassium before treatment. These precautions should be part of the decision, rather than an afterthought once tablets have been started.

Antiandrogens can interfere with the development of a male fetus. Effective contraception and discussion of future pregnancy are therefore essential whenever conception is possible. Infrequent periods do not provide contraception. Your prescriber should plan any necessary treatment changes, rather than you stopping or replacing prescribed medicine in pursuit of hair regrowth.

Diet, metformin and supplements need realistic goals

Metabolic health deserves its own attention in PCOS, even when hair thinning is the reason for seeking help. Care may include assessment of glucose, lipids and blood pressure according to the syndrome’s recommendations. This is different from a commercial “complete hair panel” offered to everyone with shedding. The international guideline does not recommend routinely available insulin measurements as a standard monitoring test.

Physical activity and balanced eating support general health, with potential benefits even when weight does not change. No particular dietary composition has demonstrated superiority across the features of PCOS. Highly restrictive eating can make adequate nutrition more difficult, so support should respect your preferences and circumstances. Hair loss is not evidence that you have failed to follow a sufficiently strict diet.

Metformin may be prescribed for particular metabolic goals, but is not an automatic treatment for thinning hair. The guideline also describes limited clinical benefits for inositol, without establishing it as a scalp regrowth treatment. A confirmed nutritional deficiency may need targeted correction, but cannot be assumed from a PCOS diagnosis alone. Supplements, oils and serums should not delay assessment when thinning continues to progress.

How can you judge whether treatment is helping?

Agree an observable goal with your clinician, such as maintaining coverage or reducing further thinning. Assessment takes months because a change in hormone levels and a visible change in hair do not necessarily follow the same timetable. Treatment may help without restoring all previous density, and the likely response depends on the hair diagnosis and how established the changes are.

Photographs taken under comparable conditions can support clinical follow-up. A different parting, direct lighting or wet hair can make the scalp look more exposed without proving that the condition has worsened. Also record side effects and practical difficulties with treatment. A modest improvement may not outweigh a treatment burden that has become unacceptable to you, and that is a valid issue to discuss.

If progress is disappointing, the prescriber can review the diagnosis, how the treatment is being used and whether an adjustment is worthwhile. Lack of improvement does not automatically make injections or surgery the next step. When offered PRP, exosomes or other procedures described as regenerative, ask what evidence specifically concerns scalp hair in people with PCOS. A proposed biological mechanism or testimonial cannot establish the expected benefit and risks for your situation.

Everyday comfort and emotional wellbeing also deserve attention

Hair concerns deserve to be heard even when thinning appears mild on examination. PCOS can affect body image, mood and relationships, and the international guideline explicitly addresses screening for anxiety and depression. Psychological support can be offered alongside hair treatment, without implying that the hair loss is simply caused by stress. You do not have to wait for severe visible thinning before discussing its effect on your life.

Appearance-focused options may meet an immediate need while longer-term care is being considered. A different hairstyle, concealing fibres or a hairpiece can make thinning less noticeable, with a cosmetic rather than a medical effect. The choice depends on comfort and personal preference. There is no obligation to conceal your hair or pursue a particular aesthetic goal.

Avoid hairstyles that pull painfully and review products if your scalp becomes irritated. These measures do not change an endocrine diagnosis, but can improve comfort and avoid additional mechanical stress. Other causes of hair loss in women still need consideration if the pattern or timing no longer fits the initial assessment. Report a change rather than assuming that every new symptom belongs to PCOS.

Can a hair transplant be considered if you have PCOS?

PCOS alone is not a reason to have a transplant. Surgical assessment may be appropriate for selected, persistent hair loss that is sufficiently stable and has a suitable donor area. If thinning also involves that area, the available options may be limited. Our hair transplantation guide explains the principles of moving existing follicles rather than creating an unlimited new supply.

Surgery does not treat PCOS or remove the need to care for non-transplanted hair. At Body Expert, a proposed hair transplant in Istanbul therefore needs an assessment of the cause of thinning, current treatment and the realistic donor possibilities. Our English-speaking patient coordinator supports communication about your plans, while medical suitability depends on your individual circumstances. Continuing medical care or deciding against surgery can be the most appropriate outcome.

Sources

Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. Read the recommendations.

Alesi, S., Forslund, M., Melin, J., Romualdi, D., Peña, A., Tay, C. T., Witchel, S. F., Teede, H., & Mousa, A. (2023). Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: A systematic review and meta-analysis of randomised controlled trials. eClinicalMedicine, 63, 102162. Read the review.

Fabbrocini, G., Cantelli, M., Masarà, A., Annunziata, M. C., Marasca, C., & Cacciapuoti, S. (2018). Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal of Women’s Dermatology, 4(4), 203–211. Read the paper.

NHS. (2026, June 30). Polyendocrine metabolic ovarian syndrome (PMOS). Read the information.

Gloucestershire Hospitals NHS Foundation Trust. (2024, January). Minoxidil for hair loss (GHPI1647). Read the leaflet.

Gloucestershire Hospitals NHS Foundation Trust. (2026, July). Spironolactone for female pattern hair loss (GHPI1956). Read the leaflet.